Document is current
Any future updates will be listed below
-
Authors
Aimer, Omar https://orcid.org/0000-0002-0874-486X
Hammad, Tarek A. https://orcid.org/0000-0001-8229-4716
Petracek, Jan https://orcid.org/0000-0003-0806-0879
Fouda, Mohamed https://orcid.org/0000-0001-6927-0410
Caro-Rojas, Angela https://orcid.org/0000-0001-9773-7188
Bate, Andrew https://orcid.org/0000-0003-3151-3653
Kugener, Veronique F. https://orcid.org/0009-0001-1755-7556
- License Information
-
More Information
Article History
Received: 1 January 2026
Accepted: 4 February 2026
First Online: 17 March 2026
Declarations
:
: No funding was received to assist with the preparation of this manuscript.
: Andrew Bate is an Editorial Board member of Drug Safety . Andrew Bate was not involved in the selection of peer reviewers for the manuscript nor was he involved in any of the subsequent editorial decisions. Andrew Bate is an employee of GSK and holds stock and stock options. The other authors have no conflicts of interest relevant to the content of this report.
: not applicable. There is no intervention in humans and because the manuscript is an Editorial containing investigators’ opinion.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Omar Aimer contributed to the conception and design of the manuscript and drafted the initial version. Tarek A. Hammad, Jan Petracek, Mohamed Fouda, Angela Caro-Rojas, Andrew Bate, Veronique F. Kugener and Omar Aimer provided critical revisions and key inputs. All authors read and approved of the final manuscript.
